Skip to content

February 2025 Research Roundup

28 February 2025

Read a research update from Martine Walmsley for February 2025.

New Phase 3 Trial Planned for Nebokitug in PSC

20 February 2025

A new trial is planned for PSC

Representing PSC Patients at the ERN RARE-LIVER Annual Meeting

01 February 2025

Martine Walmsley, PSC Support Head of Research Strategy, represented patients with rare liver diseases at the ERN RARE-LIVER annual meeting.

Register for our 20K Your Way Challenge 2025

31 January 2025

Join #TeamPSCSupport for our 20K Your Way Challenge. Choose your own 20K challenge to take on between 1st – 30th April 2025. Register now.

Breaking News from ICR

30 January 2025

Researchers at the Institute of Cancer Research (ICR) and St Mark’s Hospital in London have shared news today that they have developed a test to predict bowel cancer risk in people with inflammatory bowel disease.

Great North Run 2025 Places

23 January 2025

We’ve got places available for this iconic half marathon. Register to run for #TeamPSCSupport!

PSC Support’s 20K Your Way Challenge 2025

30 December 2024

Register your interest to find out more about our new community fundraising challenge.

Privacy Policy Update 04 December 2024

04 December 2024

We’ve updated our Privacy Policy

SPRING Clinical Trial Update

22 November 2024

Clinical Data from Phase 2 SPRING Trial Shows CM-101 Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of PSC.

Promising Preclinical Data from Rectify Pharma

22 November 2024

Rectify Pharma presented promising preclinical data for RTY-694, their lead candidate for treating primary sclerosing cholangitis and other hepatobiliary diseases, at the 75th Annual Liver Meeting® 2024.